Drug Profile
MDX 1342
Alternative Names: MDX-1342Latest Information Update: 25 Jun 2013
Price :
$50
*
At a glance
- Originator Medarex
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis
Most Recent Events
- 25 Jun 2013 No development reported - Phase-I for Chronic lymphocytic leukaemia in USA (IV)
- 25 Jun 2013 No development reported - Phase-I for Rheumatoid arthritis in Germany (IV)
- 25 Jun 2013 No development reported - Phase-I for Rheumatoid arthritis in Hungary (IV)